Stephen J. Forman

Therapeutic Targeting of the TGFβ Pathway Augments CAR T cell Efficacy in Glioblastoma

This study shows that targeting the TGFβ pathway improves CAR T cell efficacy in glioblastoma by enhancing antitumor activity and modulating the tumor microenvironment.

Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells

This study develops meditope-enabled CARs to improve T cell functionality and address tumor heterogeneity in CAR therapy.

Preclinical Proof of Concept for a personalized SNAPTM-TIL (Specific Neo-Antigen Peptides -TIL) therapy platform

This paper demonstrates a personalized SNAP-TIL therapy platform that improves TIL efficacy by enriching them with neoantigen-reactive T-cells, achieving high CD3+ cell content and significant tumor growth inhibition in preclinical models.

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment

Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.

Focal radiotherapy improves CAR T cell therapy targeting prostate cancer

This study combines focal radiotherapy, cyclophosphamide, and PSCA-CAR T cells to enhance antitumor responses and survival in prostate cancer models.

Longitudinal single cell RNA-sequencing reveals evolution of micro- and macro-states in chronic myeloid leukemia

The paper shows that clinically relevant leukemia phenotypes emerge at the macrostate level from single cell data, revealing how disease states aggregate from noisy single cell transcriptomes.

IL12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer

This study develops and tests IL12-engineered human PSMA-CAR T cells for advanced prostate cancer, showing improved anti-tumor activity and safety.

Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy

This study identifies immunometabolic factors in CD19 CAR T cells that predict long-term response in B-ALL patients and suggests mTOR inhibition as a strategy to enhance anti-tumor activity.

Whole-Proteome Screening and Multi-Modal Profiling of Antigen-Specific CD4+ T Cells at Single-Cell Resolution

The paper develops a high-throughput platform to profile antigen-specific CD4+ T cells at single-cell resolution, identifying immunogenic features and functional heterogeneity in viral and cancer contexts.

Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1

This study identifies SPP1+ macrophages as key drivers of resistance to CAR T therapy in solid tumors and shows that targeting SPP1 can overcome this resistance.